~~<i id='56DF00E2C3'><strike id='56DF00E2C3'><tt id='56DF00E2C3'><pre id='56DF00E2C3'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

comprehensive

author：Wikipedia 2025-08-27 16:45:29 - browse：7397

Eli Lilly said Friday that it will acquire Dermira, a small biotech developing drugs for chronic skin conditions, for $1.1 billion.

The centerpiece of the deal is the Dermira drug called lebrikizumab that aims to treat people suffering from moderate-to-severe atopic dermatitis, the most common form of eczema, a disease characterized by inflamed, itchy, and scaly skin.

Phase 3 clinical trials of lebrikizumab in atopic dermatitis are underway. If successful, the drug could compete against Dupixent, which has grown into a commercial blockbuster for Regeneron Pharmaceuticals and Sanofi.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： The pink breast cancer awareness ribbon needs a redesign

Wikipedia

focus

Wikipedia

hotspot

explore

entertainment

AndrewHarnik/APWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnews

WSS

Maker of FluMist seeks to allow at

Overprescribed: High cost isn't America's only drug problem

Hospitals warn Medicare's drug payment fix is ‘unlawful’

Bird flu reported in person exposed to presumably infected cattle

The pink breast cancer awareness ribbon needs a redesign

Insurer loopholes limit power of law against surprise medical bills

leisure time

comprehensive

Wikipedia

Psychedelics group wrestles with new pharma identity

Covid silver lining: Unprecedented look at human immune system

Peter Hotez and the public health issue of online harassment

Harvard scientists, with Google, unveil the most detailed brain map ever

Tori Bowie and the unacceptable rates of Black maternal death

Pancreatic cancer is often deadly, but new discoveries are raising hope

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Covid silver lining: Unprecedented look at human immune system

Hollywood unions extend contract negotiations for actors

Alzheimer's risk factor APOE4 may be a distinct form of the disease

focus

Testing for cancer recurrence creates a new limbo for patients

Multiple sclerosis has subtypes with different best treatments: study

FDA has safety concerns on CRISPR

Republican states more likely to report Covid vaccine side effects

Why Sanofi got shellacked over its spinoff

Biden's order seeks to regulate AI risk without stifling innovation

Wikipedia

hotspot

explore

entertainment